

## **Competition approvals obtained for the public tender offer by Asahi Kasei Pharma Denmark A/S for the shares and warrants in Veloxis Pharmaceuticals A/S**

**The Competition Authorities have either approved of the offer and issued the necessary permits, or declared that they do not have any objections to the offer, as conditioned in the offer document.**

Asahi Kasei Pharma Denmark A/S, a wholly owned subsidiary of Asahi Kasei Corporation, announces that it has now received all necessary regulatory approvals, permits and consents from the Competition Authorities relating to the offer.

With the minimum tender condition of more than 80% of the shares and warrants of Veloxis Pharmaceuticals A/S also having been satisfied through irrevocable tenders, all conditions of the offer are expected to be satisfied upon or prior to the expiry of the offer period.

After completing the offer, Asahi Kasei Pharma Denmark A/S intends to delist the shares of Veloxis Pharmaceuticals A/S from Nasdaq Copenhagen, which is expected to reduce the liquidity of the shares of Veloxis Pharmaceuticals A/S significantly. Shareholders are notified that Nasdaq Copenhagen on 7 January 2020 has published new rules for issuers of shares to have the shares removed from trading on Nasdaq Copenhagen. The rules which will come into force on 15 February 2020 will facilitate that Asahi Kasei Pharma Denmark A/S after completion of the offer will be able to delist the shares from trading on Nasdaq Copenhagen in accordance with the requirements of the listing rules.

**Accordingly, all shareholders and/or warrant holders who have yet to tender their shares and/or warrants are encouraged to do so in advance of the expiry of the offer period on 14 January 2020 at 17:00 (CET).**

The offer document can be viewed and downloaded at <http://ir.veloxis.com/voluntary-public-offer>.

Copenhagen, 9 January 2020

Asahi Kasei Pharma Denmark A/S

### **Disclaimer**

The offer is made neither directly nor indirectly in any jurisdiction where this would constitute a violation of the legislation within the jurisdiction in question. This announcement and other documents regarding the offer must not be sent, forwarded or distributed in any other way within a jurisdiction where this would constitute a violation of legislation within said jurisdiction, including in particular in Canada, Japan, Australia or South Africa. This announcement does not constitute an offer or invitation to sell or buy shares in Veloxis Pharmaceuticals A/S. The offer is made solely on the basis of an offer document prepared and published by Asahi Kasei Pharma Denmark A/S which contains the complete terms and conditions of the offer. Shareholders and warrant holders in Veloxis Pharmaceuticals A/S are encouraged to read the offer document, the board statement and any associated documents as these will contain important information on the offer.

The offer is being made in the United States of America in accordance with Section 14(e) of, and Regulation 14E promulgated under, the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act"), subject, with respect to the offer to purchase outstanding shares, to the exemption provided by Rule 14d-1(c) under the Exchange Act and otherwise in accordance with the requirements of Danish law. Pursuant to one or more exemptions provided in Rule 14e-5(b) of the Exchange Act, Asahi Kasei Pharma Denmark A/S or its nominees, or its brokers (acting as agents of Asahi Kasei Pharma Denmark A/S or in a similar capacity), may, from time to time, purchase or make arrangements to purchase Veloxis Pharmaceuticals A/S shares and warrants outside of the United States, other than pursuant to the offer during the period where the offer remains open for acceptance.